The company also announced the appointment of Jakob Wedel as chief strategy and corporate development officer. Its c-suite continues to undergo a makeover following the appointment of a new CEO last year amid its long-running battle to acquire Grail.
Goswami, who held both roles now filled by Illumina, decided to depart the DNA sequencing and array-based technology developer. He plans to stay on in an advisory role through June 30 to support the new executive appointments. Goswami originally joined the company in 2019.
Dhingra most recently served as CFO at Summit Therapeutics and brings experience from the life sciences, diagnostics and pharmaceutical industries. He previously served as CFO of CareDx and, before that, spent 18 years at Agilent Technologies.
Wedel joined Illumina in November 2023 as CEO chief of staff, leading strategic transformation initiatives. In his new role, his responsibilities include driving strategic planning, partnerships and acquisitions. His previous experience includes time as a partner at EY’s strategy practice, co-leading the company’s global life science practice. He also served in roles at McKinsey & Company and Bain & Company. In the early 2000s, Wedel co-founded Nordic strategy firm Qvartz, which Bain later acquired.
“I am proud of the talent joining our management team as we work to deliver on Illumina’s mission to improve human health by unlocking the power of the genome,” said Jacob Thaysen, Illumina CEO. “Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina’s CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms. Both are deeply committed to serving our customers and helping Illumina grow.
“We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions. Joydeep will continue with us for several weeks to support a smooth leadership transition.”
